Table 2 Pattern of involvements in patients with NSC region metastases and incidence of NSC lesions in different groups
SVZ | P | Hippocampusa | P | |
|---|---|---|---|---|
No. of involved patients (%) | 15a (6.3%) | _ | 14a (5.9%) | _ |
No. of specific metastases in involved patients (%) | 15 (1.0%) | _ | 15b (1.0%) | _ |
Total Number of intracranial metastases | ||||
Oligometastatis pts | 0/150 (0.0%) | 0.000 | 1/150 (0.7%) | 0.000 |
Non-oligometastatic pts | 15/88 (17.0%) | 13/88 (14.8%) | ||
Therapy processes | ||||
BMs identified at Diagnosis | 3/97 (3.1%) | 0.109 | 6/97 (6.2%) | 1.000 |
BMs identified during or after treatments | 12/141 (8.5%) | 8/141 (5.7%) | ||
Symptoms | ||||
Symptomatic BMs | 5/65 (7.7%) | 0.561 | 1/65 (1.5%) | 0.120 |
Asymptomatic BMs | 10/173 (5.8%) | 13/173 (7.5%) | ||